BR112014018712A8 - Derivados de morfolinila úteis como inibidores de mogat-2 - Google Patents

Derivados de morfolinila úteis como inibidores de mogat-2

Info

Publication number
BR112014018712A8
BR112014018712A8 BR112014018712A BR112014018712A BR112014018712A8 BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8 BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A BR112014018712 A BR 112014018712A BR 112014018712 A8 BR112014018712 A8 BR 112014018712A8
Authority
BR
Brazil
Prior art keywords
morpholinil
mogat
inhibitors
derivatives useful
compounds
Prior art date
Application number
BR112014018712A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014018712A2 (https=
Inventor
Rosario Gonzalez-Garcia Maria
Carmen Fernandez Maria
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48905712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014018712(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112014018712A2 publication Critical patent/BR112014018712A2/pt
Publication of BR112014018712A8 publication Critical patent/BR112014018712A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112014018712A 2012-01-31 2013-01-24 Derivados de morfolinila úteis como inibidores de mogat-2 BR112014018712A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12382037 2012-01-31
US201261617093P 2012-03-29 2012-03-29
EP12382433 2012-11-06
PCT/US2013/022828 WO2013116065A1 (en) 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as mogat-2 inhibitors

Publications (2)

Publication Number Publication Date
BR112014018712A2 BR112014018712A2 (https=) 2017-06-20
BR112014018712A8 true BR112014018712A8 (pt) 2017-07-11

Family

ID=48905712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018712A BR112014018712A8 (pt) 2012-01-31 2013-01-24 Derivados de morfolinila úteis como inibidores de mogat-2

Country Status (23)

Country Link
US (1) US8993568B2 (https=)
EP (1) EP2809661B1 (https=)
JP (1) JP5852269B2 (https=)
KR (1) KR20140107641A (https=)
CN (1) CN104080777B (https=)
AP (1) AP2014007793A0 (https=)
AU (1) AU2013215549B2 (https=)
BR (1) BR112014018712A8 (https=)
CA (1) CA2859992A1 (https=)
CL (1) CL2014001862A1 (https=)
CO (1) CO7020914A2 (https=)
CR (1) CR20140325A (https=)
DO (1) DOP2014000177A (https=)
EA (1) EA024182B1 (https=)
ES (1) ES2571577T3 (https=)
GT (1) GT201400169A (https=)
IL (1) IL233542A0 (https=)
MX (1) MX2014008604A (https=)
PE (1) PE20141789A1 (https=)
PH (1) PH12014501712B1 (https=)
SG (1) SG11201404508XA (https=)
WO (1) WO2013116065A1 (https=)
ZA (1) ZA201405227B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Mogat−2阻害剤として有用な新規モルホリニル誘導体
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
US10335401B2 (en) 2015-12-21 2019-07-02 Shionogi & Co., Ltd. Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
CA3126334A1 (en) 2019-01-11 2020-07-16 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO2000006539A1 (en) 1998-07-31 2000-02-10 Eli Lilly And Company Alkenyl sulphonamide derivatives
AU5235699A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Sulfonamide derivatives
GB0408777D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
US8232282B2 (en) 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
US20090203695A1 (en) * 2007-12-05 2009-08-13 Biovitrum Ab Compounds IV
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物v
US20110275647A1 (en) 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Mogat−2阻害剤として有用な新規モルホリニル誘導体
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.

Also Published As

Publication number Publication date
CN104080777B (zh) 2015-12-09
EA024182B1 (ru) 2016-08-31
CR20140325A (es) 2014-08-25
JP2015504917A (ja) 2015-02-16
ZA201405227B (en) 2016-05-25
EP2809661A1 (en) 2014-12-10
HK1199024A1 (zh) 2015-06-19
AP2014007793A0 (en) 2014-07-31
US8993568B2 (en) 2015-03-31
PH12014501712A1 (en) 2014-10-13
AU2013215549A1 (en) 2014-07-17
CA2859992A1 (en) 2013-08-08
PE20141789A1 (es) 2014-11-19
MX2014008604A (es) 2014-08-22
PH12014501712B1 (en) 2014-10-13
EP2809661B1 (en) 2016-04-06
IL233542A0 (en) 2014-08-31
GT201400169A (es) 2015-08-27
BR112014018712A2 (https=) 2017-06-20
AU2013215549B2 (en) 2015-09-03
DOP2014000177A (es) 2014-08-31
WO2013116065A1 (en) 2013-08-08
JP5852269B2 (ja) 2016-02-03
CO7020914A2 (es) 2014-08-11
ES2571577T3 (es) 2016-05-26
KR20140107641A (ko) 2014-09-04
US20150005305A1 (en) 2015-01-01
EA201491227A1 (ru) 2015-01-30
CN104080777A (zh) 2014-10-01
CL2014001862A1 (es) 2014-11-14
SG11201404508XA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
BR112014027236A2 (pt) pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
ECSP14013211A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
BR112014018636A8 (pt) Derivados de benzil sulfonamida úteis como inibidores de mogat-2
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112015004547A8 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BR112016007396A2 (pt) derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos
BR112014018712A8 (pt) Derivados de morfolinila úteis como inibidores de mogat-2
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
BR112015004029A8 (pt) processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo, e, composto
BR112015003698A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método para o tratamento de câncer
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112016013946A8 (pt) quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit
BR112015007312A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
EA201590656A1 (ru) Азаиндолины
BR112015003201A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer
BR112015009567A2 (pt) compostos de benzil sulfonamida novos úteis como inibidores de mogat-2
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]